Itraconazole and MK-2828 for Drug Interaction Study

This trial aims to understand how the body processes the drug MK-2828 when taken with itraconazole and how it interacts with midazolam. Researchers are testing whether the levels of MK-2828 change when combined with itraconazole compared to when taken alone. They also seek to determine if MK-2828 affects the level of midazolam in the body. The study seeks healthy individuals without a history of major diseases like cancer or serious heart and liver problems. As a Phase 1 trial, the research focuses on understanding how the treatment works in people, offering participants the opportunity to be among the first to receive this new treatment.

The trial information does not specify if you need to stop taking your current medications. It's best to discuss this with the trial coordinators.

Research has shown that itraconazole is usually well-tolerated by patients. Common side effects include nausea, vomiting, and dizziness, similar to other itraconazole products. However, itraconazole can interact with many other medications, so caution is necessary when taking other drugs.

Midazolam, another treatment in the study, is generally safe but can cause relaxation or sleepiness. Some serious side effects, such as breathing problems, have been reported, especially when combined with other medications.

Researchers are excited about these treatments because they explore potential drug interactions between Itraconazole, Midazolam, and MK-2828. Itraconazole is a well-known antifungal medication, but in this context, it’s being used to study how it interacts with MK-2828, potentially influencing its metabolism or effectiveness. Midazolam, a sedative, is also being paired with MK-2828 to observe similar interactions. By understanding these interactions, researchers hope to uncover new ways to optimize the use of MK-2828, potentially enhancing its therapeutic benefits or reducing side effects when used alongside other medications.

This trial will study the interactions between Itraconazole and MK-2828, as well as between Midazolam and MK-2828. Research has shown that itraconazole can alter the effects of other drugs by strongly inhibiting a liver enzyme called CYP3A, which helps break down drugs. Studies have found that itraconazole can significantly raise the levels of other drugs, like dordaviprone, in the body. In this trial, participants in one arm will receive multiple oral doses of Itraconazole with a single oral dose of MK-2828.